Athira Pharma (NASDAQ:ATHA) Trading Up 6.3% – Time to Buy?
by Tristan Rich · The Markets DailyShares of Athira Pharma, Inc. (NASDAQ:ATHA – Get Free Report) were up 6.3% on Wednesday . The company traded as high as $11.91 and last traded at $11.68. Approximately 41,461 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 3,210,973 shares. The stock had previously closed at $10.99.
Athira Pharma Stock Down 0.4%
The business has a fifty day simple moving average of $7.14 and a two-hundred day simple moving average of $5.74. The company has a market cap of $37.63 million, a P/E ratio of -0.99 and a beta of 2.79.
Institutional Trading of Athira Pharma
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Focus Partners Wealth purchased a new stake in Athira Pharma in the third quarter worth about $35,000. Jane Street Group LLC purchased a new stake in Athira Pharma in the fourth quarter worth about $100,000. Renaissance Technologies LLC increased its position in Athira Pharma by 44.7% in the fourth quarter. Renaissance Technologies LLC now owns 75,147 shares of the company’s stock worth $569,000 after buying an additional 23,223 shares in the last quarter. Seven Fleet Capital Management LP purchased a new stake in Athira Pharma in the fourth quarter worth about $969,000. Finally, Millennium Management LLC purchased a new stake in Athira Pharma in the fourth quarter worth about $2,456,000. Hedge funds and other institutional investors own 57.12% of the company’s stock.
About Athira Pharma
Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).
The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.